CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
Lasmiditan +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03308669
NCT03308669Phase 1Completed
CompareCT.gov

Safety, Tolerability, and Pharmacokinetics of Lasmiditan When Co-administered With Topiramate in Healthy Subjects

Eli Lilly and Company·interventional·Posted Oct 12, 2017·Updated Nov 27, 2019

In Brief

A Phase 1 clinical trial evaluating Lasmiditan, Placebo, and 1 other intervention for Healthy. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This study will assess the safety, tolerability and blood concentrations of lasmiditan and topiramate together compared to lasmiditan and topiramate separately. Information about any side effects that may occur will be collected. Participants will be admitted to the Clinical Research Unit (CRU) one day prior to the start of the study and will remain through Day 14. This study is expected to last approximately 25 days, not including screening. Screening is required within 28 days prior to the start of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedOct 12, 2017
Enrollment StartOct 16, 2017
Primary CompletionDec 2, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.7 years ago

Interventions

Lasmiditandrug

Administered orally

Placebodrug

Administered orally

Topiramatedrug

Administered orally